Abstract Background SARS-CoV-2 variant Beta (B. 1.351) was designated as a Variant of
Concern (VoC) after becoming the dominant strain in South Africa and spreading …

Background: Following emergency use authorization of the Pfizer/BioNTech mRNA SARS-
CoV-2 vaccine, BNT162b2, the Ministry of Health (MoH) launched a campaign to immunize …

Background COVID-19 vaccines provide protection against symptomatic infection that might
require medical attention and against severe outcomes; however, there is a paucity of …

Objective To evaluate the effectiveness of the Pfizer BNT162b2 vaccine against the SARS-
Cov-2 Beta variant. Study Design and Setting Israel's mass vaccination program, using two …

Evidence of BNT126b2 vaccine effectiveness and breakthrough has been primarily
demonstrated in populations outside of Asia; studies in the Western Pacific region are …

In the preregistration trial, data on efficacy of BNT162b2 mRNA vaccine against SARS-CoV-
2 infection were not collected. This study aimed to evaluate vaccine effectiveness (VE) …

Vaccine breakthrough SARS-CoV-2 infection has been monitored in 3720 healthcare
workers receiving 2 doses of BNT162b2. SARS-CoV-2 infection is detected in 33 subjects …

Objective This study examined the initial impact of a national BNT162b2 vaccine rollout on
SARS-CoV-2 infections in Qatar. Methods All individuals who had completed≥ 14 days of …

A retrospective cohort study was carried out in a large Israeli health maintenance
organization to determine vaccine effectiveness (VE) of a third dose of BNT162b2 vaccine …

Summary Background Hong Kong maintained low circulation of SARS-CoV-2 until a major
community epidemic of the omicron (B. 1.1. 529) sublineage BA. 2 began in January, 2022 …